TSX-V:KHRN - TSX Venture Exchange - CA49374L3065 - Common Stock - Currency: CAD
Taking everything into account, KHRN scores 2 out of 10 in our fundamental rating. KHRN was compared to 35 industry peers in the Pharmaceuticals industry. KHRN may be in some trouble as it scores bad on both profitability and health. KHRN is valued quite expensive, but it does show an excellent growth.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | N/A | ||
ROE | N/A | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 19.51% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.05 | ||
Debt/FCF | N/A | ||
Altman-Z | -5.28 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 1.91 | ||
Quick Ratio | 0.91 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
TSX-V:KHRN (5/5/2023, 7:00:00 PM)
0.04
0 (0%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 0.45 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 0.27 | ||
P/tB | 0.36 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | N/A | ||
ROE | N/A | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 19.51% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.05 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 143.78% | ||
Cap/Sales | N/A | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 1.91 | ||
Quick Ratio | 0.91 | ||
Altman-Z | -5.28 |